Abstract: A method for treating HER2 positive breast cancer in a subject in need thereof includes administering to cancer cells of the subject an agent effective to modulate the level of HER2-associated RNA in the breast cancer cells of the subject.

Abstract: In a predictive outcome assessment test for predicting whether a patient undergoing a breast cancer treatment regimen will achieve pathological complete response (pCR), differential gene expression level information are generated for an input set of genes belonging to the TGF-? signaling pathway. The differential gene expression level information compares baseline gene expression level information from a baseline sample (70) of a breast tumor of a patient acquired before initiating (71) a breast cancer therapy regimen to the patient and response gene expression level information from a response sample (72) of the breast tumor acquired after initiating the breast cancer therapy regimen by administering a first dose of bevacizumab to the patient. A pCR prediction for the patient is computed based on the differential gene expression level information for the input set of genes belonging to the TGF-? signaling pathway. Related predictive outcome assessment test development methods are also disclosed.

Abstract: Methods, apparatus, and other embodiments distinguish disease phenotypes and mutational status using co-occurrence of local anisotropic gradient orientations (CoLIAGe) and Laws features. One example apparatus includes a set of circuits that acquires a radiologic image (e.g., MRI image) of a region of tissue demonstrating breast cancer, computes a gradient orientation for a pixel in the MRI image, computes a significant orientation for the pixel based on the gradient orientation, constructs a feature vector that captures a discretized entropy distribution for the image based on the significant orientation, extracts a set of texture features from the MRI image, and classifies the phenotype of the breast cancer based on the feature vector and the set of texture features. Embodiments of example apparatus may generate and display a heatmap of entropy values for the image. Example methods and apparatus may operate substantially in real-time, or may operate in two, three, or more dimensions.

Abstract: A method for treating HER2 positive breast cancer in a subject in need thereof includes administering to cancer cells of the subject an agent effective to modulate the level of HER2-associated RNA in the breast cancer cells of the subject.

Abstract: Methods, apparatus, and other embodiments distinguish disease phenotypes and mutational status using co-occurrence of local anisotropic gradient orientations (CoLIAGe) and Laws features. One example apparatus includes a set of circuits that acquires a radiologic image (e.g., MRI image) of a region of tissue demonstrating breast cancer, computes a gradient orientation for a pixel in the MRI image, computes a significant orientation for the pixel based on the gradient orientation, constructs a feature vector that captures a discretized entropy distribution for the image based on the significant orientation, extracts a set of texture features from the MRI image, and classifies the phenotype of the breast cancer based on the feature vector and the set of texture features. Embodiments of example apparatus may generate and display a heatmap of entropy values for the image. Example methods and apparatus may operate substantially in real-time, or may operate in two, three, or more dimensions.

Abstract: In a predictive outcome assessment test for predicting whether a patient undergoing a breast cancer treatment regimen will achieve pathological complete response (pCR), differential gene expression level information are generated for an input set of genes belonging to the TGF-? signaling pathway. The differential gene expression level information compares baseline gene expression level information from a baseline sample (70) of a breast tumor of a patient acquired before initiating (71) a breast cancer therapy regimen to the patient and response gene expression level information from a response sample (72) of the breast tumor acquired after initiating the breast cancer therapy regimen by administering a first dose of bevacizumab to the patient. A pCR prediction for the patient is computed based on the differential gene expression level information for the input set of genes belonging to the TGF-? signaling pathway. Related predictive outcome assessment test development methods are also disclosed.